DUPA

Target: This ligand targets prostate-specific membrane antigen FOLH1/PSMA in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for prostate-specific membrane antigen FOLH1/PSMA. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings prostate-specific membrane antigen FOLH1/PSMA into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Degradation: DUPA can be used as a binding ligand to recruit a target protein within PROTAC constructs, enabling ubiquitin–proteasome–dependent degradation rather than simple inhibition. In research settings, DUPA-based chimeras can help map degradation potency, define effective ternary complex formation, and evaluate how ligand engagement translates into protein turnover.

• Ternary Complex Optimization: Incorporating DUPA into PROTAC designs supports systematic tuning of linker length and attachment geometry to enhance cooperative binding. This enables researchers to probe how DUPA-mediated target engagement affects formation and stability of the target–PROTAC–E3 ligase ternary complex, guiding selection of constructs with improved degradation efficiency and reduced off-target stabilization.

• E3 Ligase Recruitment Studies: DUPA-containing PROTACs can be leveraged to compare degradation outcomes across different E3 ligases by swapping the recruiting moiety while keeping the DUPA target-binding element constant. Such studies clarify whether DUPA-driven target positioning favors specific ubiquitination pathways, informing rational selection of E3 partners for robust, selective degradation.

• Mechanism-of-Action Mapping: Using DUPA in PROTAC platforms allows investigation of degradation mechanisms, including ubiquitination dependence and proteasome requirement. Researchers can quantify time- and dose-dependent loss of the target protein, assess rescue by proteasome or neddylation pathway perturbation, and distinguish between degradation and occupancy-driven effects to refine mechanistic understanding.

DUPA is a PSMA-targeting ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of DUPA is characterized by carboxylic acid or carboxylate handle. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The acid handle supports amide coupling with amino-PEG, alkyl-diamine, piperazine, or aminoalkyl E3-ligase ligands. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.